Sandra Villegas

List of Publications by Year
in descending order

61 papers	1,514 citations	331538 21 h-index	330025 37 g-index
62 all docs	62 docs citations	62 times ranked	1844 citing authors

#	Article	IF	Citations
1	Production of Therapeutic Single-Chain Variable Fragments (ScFv) in Pichia pastoris. Methods in Molecular Biology, 2022, 2313, 151-167.	0.4	2
2	Amyloid-beta peptide and tau protein crosstalk in Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
3	Low-density lipoprotein aggregation is inhibited by apolipoprotein J-derived mimetic peptide D-[113â€“122]apoJ. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158541.	1.2	7
4	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimerâ€™s Disease is Affected by AÎ²-ImmunoTherapy and Cognitive Stimulation. Pharmaceutics, 2020, 12, 944.	2.0	17
5	Both Amyloid-Î² Peptide and Tau Protein Are Affected by an Anti-Amyloid-Î² Antibody Fragment in Elderly 3xTg-AD Mice. International Journal of Molecular Sciences, 2020, 21, 6630.	1.8	10
6	Progression of Alzheimer's disease and effect of scFvâ€h3D6 immunotherapy in the 3xTgâ€AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy. NMR in Biomedicine, 2020, 33, e4263.	1.6	13
7	Apolipoprotein J Mimetic Peptide D-[113â€“122]Apoj Retard Atherosclerosis In Ldlr-Ko Mice Under Atherogenic Diet By Improving Hdl Function And Decreasing Ldl Aggregability. Atherosclerosis, 2019, 287, e200-e201.	0.4	0
8	Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-Î² Burden. Journal of Alzheimer's Disease, 2019, 70, 1069-1091.	1.2	18
9	Pharmacokinetic parameters and mechanism of action of an efficient anti-AÎ² single chain antibody fragment. PLoS ONE, 2019, 14, e0217793.	1.1	9
10	Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 1302-1316.	1.4	10
11	The Role of Apolipoprotein E Isoforms in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 459-471.	1.2	21
12	AÎ²-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-AÎ² single chain variable fragment in combination with an apoE mimetic peptide. Molecular and Cellular Neurosciences, 2018, 89, 49-59.	1.0	21
13	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering, 2018, 19, 59-67.	3.8	8
14	Differential effects of apoE and apoJ mimetic peptides on the action of an anti-AÎ² scFv in 3xTg-AD mice. Biochemical Pharmacology, 2018, 155, 380-392.	2.0	17
15	Understanding the contribution of disulfide bridges to the folding and misfolding of an antiâ€AÎ² scFv. Protein Science, 2017, 26, 1138-1149.	3.1	12
16	Mouse Models of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 57, 1171-1183.	1.2	201
17	Apolipoprotein J mimetic peptide [113â€“122]apoj decreases weight gain in LDLR-KO mice under atherogenic diet by decreasing fat accumulation. Atherosclerosis, 2017, 263, e71.	0.4	1
18	Towards the improvement in stability of an anti-AÎ² single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 167-175.	1.4	8

#	Article	IF	Citations
19	An Intracellular Amyloid-Î²/AÎ²PP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 59, 1079-1096.	1.2	15
20	Production of an anti-AÎ² antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect. PLoS ONE, 2017, 12, e0181480.	1.1	25
21	Effects of an AÎ²-antibody fragment on AÎ² aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides. PLoS ONE, 2017, 12, e0188191.	1.1	12
22	Common features in the unfolding and misfolding of PDZ domains and beyond: the modulatory effect of domain swapping and extra-elements. Scientific Reports, 2016, 6, 19242.	1.6	9
23	AÎ²-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Reviews in Molecular Medicine, 2016, 18, e13.	1.6	34
24	Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication, 2016, 8, 025001.	3.7	15
25	The chondroitin sulfate/dermatan sulfate 4-O-endosulfatase from marine bacterium Vibrio sp FC509 is a dimeric species: Biophysical characterization of an endosulfatase. Biochimie, 2016, 131, 85-95.	1.3	9
26	Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories, 2016, 15, 166.	1.9	32
27	AÎ² immunotherapy for Alzheimer's disease: where are we?. Neurodegenerative Disease Management, 2016, 6, 179-181.	1.2	8
28	Prospective Therapies for Alzheimer Disease: Biomarkers, Clinical Trials and Preclinical Research. , 2016, , 114-191.		3
29	Cerebellar cortex development in the weaver condition presents regional and age-dependent abnormalities without differences in Purkinje cells neurogenesis. Acta Neurobiologiae Experimentalis, 2016, 76, 53-65.	0.4	2
30	Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils. Protein Science, 2015, 24, 1829-1840.	3.1	31
31	Alzheimer's disease: New therapeutic strategies. Medicina ClÃnica (English Edition), 2015, 145, 76-83.	0.1	0
32	Apolipoprotein J protects against LDL aggregation. Atherosclerosis, 2015, 241, e124.	0.4	0
33	Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. FASEB Journal, 2015, 29, 1688-1700.	0.2	25
34	Protein structures in Alzheimer's disease: The basis for rationale therapeutic design. Archives of Biochemistry and Biophysics, 2015, 588, 1-14.	1.4	20
35	A thermodynamic study of the third PDZ domain of MAGUK neuronal protein PSD-95 reveals a complex three-state folding behavior. Biophysical Chemistry, 2014, 185, 1-7.	1.5	11
36	The isolated N terminus of Ring1B is a well-folded, monomeric fragment with native-like structure. Protein Engineering, Design and Selection, 2014, 27, 1-11.	1.0	2

#	Article	IF	Citations
37	The Impact of Extra-Domain Structures and Post-Translational Modifications in the Folding/Misfolding Behaviour of the Third PDZ Domain of MAGUK Neuronal Protein PSD-95. PLoS ONE, 2014, 9, e98124.	1.1	8
38	Principal Component and Cluster Analysis of Morphological Variables Reveals Multiple Discrete Sub-phenotypes in Weaver Mouse Mutants. Cerebellum, 2013, 12, 406-417.	1.4	6
39	Early intervention in the 3xTg-AD mice with an amyloid Î²-antibody fragment ameliorates first hallmarks of Alzheimer disease. MAbs, 2013, 5, 665-864.	2.6	48
40	Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid Î² antibody fragment. MAbs, 2013, 5, 660-664.	2.6	24
41	Elongation of the C-terminal domain of an anti-amyloid Î² single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency. MAbs, 2013, 5, 678-689.	2.6	16
42	Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding. Current Opinion in Lipidology, 2012, 23, 479-486.	1.2	41
43	The Interconversion between a Flexible Î²-Sheet and a Fibril Î²-Arrangement Constitutes the Main Conformational Event during Misfolding of PSD95-PDZ3 Domain. Biophysical Journal, 2012, 103, 738-747.	0.2	11
44	An anti-AÎ² (amyloid Î²) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing AÎ² oligomers from the amyloid pathway. Biochemical Journal, 2011, 437, 25-34.	1.7	36
45	Prediction of a new class of RNA recognition motif. Journal of Molecular Modeling, 2011, 17, 1863-1875.	0.8	1
46	2D-NMR reveals different populations of exposed lysine residues in the apoB-100 protein of electronegative and electropositive fractions of LDL particles. Journal of Lipid Research, 2010, 51, 1560-1565.	2.0	20
47	Aggregated Electronegative Low Density Lipoprotein in Human Plasma Shows a High Tendency toward Phospholipolysis and Particle Fusion. Journal of Biological Chemistry, 2010, 285, 32425-32435.	1.6	46
48	High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level. Journal of Lipid Research, 2009, 50, 446-455.	2.0	31
49	Influence of Aggregation Propensity and Stability on Amyloid Fibril Formation As Studied by Fourier Transform Infrared Spectroscopy and Two-Dimensional COS Analysis. Biochemistry, 2009, 48, 10582-10590.	1.2	28
50	Novel Phospholipolytic Activities Associated with Electronegative Low-Density Lipoprotein Are Involved in Increased Self-Aggregation. Biochemistry, 2008, 47, 8186-8194.	1.2	40
51	Early Kinetics of Amyloid Fibril Formation Reveals Conformational Reorganisation of Initial Aggregates. Journal of Molecular Biology, 2007, 366, 1351-1363.	2.0	60
52	M.461 Impaired affinity binding of electronegative LDL (LDL($minus;)) to the LDL receptor (LDLR). Relationship with APOB structure, non-esterified fatty acids (NEFA) and lysophosphatidylcholine (LPC) content. Atherosclerosis, 2004, 5, 107.	0.4	0
53	Protein secondary structure and stability determined by combining exoproteolysis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Journal of Mass Spectrometry, 2002, 37, 974-984.	0.7	16
54	Comparative Analysis of the Sequences and Three-Dimensional Models of Human Procarboxypeptidases A1, A2 and B. Biological Chemistry, 1998, 379, 149-156.	1.2	13

#	Article	IF	Citations
55	Favourable native-like helical local interactions can accelerate protein folding. Folding & Design, 1997, 2, 23-33.	4.5	92
56	Stabilization of proteins by rational design of Î±-helix stability using helix/coil transition theory. Folding & Design, 1996, 1, 29-34.	4.5	83
57	Evidence for a Two-State Transition in the Folding Process of the Activation Domain of Human Procarboxypeptidase A2. Biochemistry, 1995, 34, 15105-15110.	1.2	99
58	Pancreatic Procarboxypeptidases: Their Activation Processes Related to the Structural Features of the Zymogens and Activation Segments. Biological Chemistry Hoppe-Seyler, 1992, 373, 387-392.	1.4	12
59	Analysis of the activation process of porcine procarboxypeptidase B and determination of the sequence of its activation segment. Biochemistry, 1991, 30, 4082-4089.	1.2	50
60	Expression of heat-labile enterotoxin genes is under cyclic AMP control inEscherichia coli. Current Microbiology, 1990, 20, 83-90.	1.0	11
61	Modified Forms of LDL in Plasma. , 0, , .		0